Can a Primary Care Doctor Prescribe HRT?
Not sure which door is yours?
Match your symptoms, age, uterus status, risk history, insurance, state, and medication route before choosing primary care, an OB-GYN, or online HRT care.
Can a primary care doctor prescribe HRT? Yes—in the United States, when the treatment is clinically appropriate and within that clinician's state scope of practice. You do not automatically need an OB-GYN. The real constraint is usually not legal authority; it is whether that practice evaluates menopause and is comfortable managing the medication and follow-up.
Primary care is a good first stop if: your symptoms fit typical perimenopause or menopause · you want the visit billed to insurance and the prescription filled at your own pharmacy · your doctor already knows your history and medications · your symptoms could have more than one cause and you want the whole picture checked.
Primary care is not the right first stop if: you have bleeding after menopause or unexplained vaginal bleeding that has not been evaluated · you have symptoms that need urgent care · your history calls for coordinated cancer, clotting, cardiovascular, liver, or gynecologic review · you are looking specifically for pellets, a compounded preparation, or testosterone and your PCP does not manage those categories.
Scope: This guide covers U.S. care for perimenopause and menopause in women. It does not cover gender-affirming hormone therapy or testosterone replacement for male hypogonadism. Those follow different prescribing, monitoring, and coverage paths.
The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.
Can a primary care doctor prescribe HRT? Start with these four answers
Yes. Your family medicine or internal medicine clinician can evaluate menopause symptoms and prescribe menopausal hormone therapy when it fits your history and falls within that clinician's scope. You need a specialist only when your history, symptoms, examination needs, or the practice's own limits make specialist input the better route.
| Your question | The bottom line |
|---|---|
| Can a primary care doctor prescribe HRT? | Yes — when it is clinically appropriate and within the clinician's prescribing scope. No separate federal menopause certification is required. |
| Do you automatically need an OB-GYN? | No. A PCP can prescribe directly or refer when your situation needs specialist input. |
| Is every PCP comfortable doing it? | No. In a 2017 survey of residents from 20 U.S. training programs, only 6.8% of respondents said they felt adequately prepared to manage menopause. |
| Do you need hormone blood tests first? | Usually not when you are over 45 with typical symptoms. Current federal and endocrine guidance says fluctuating hormone levels often make a single test unhelpful for diagnosing the menopause transition. |
Source: Kling et al., Mayo Clinic Proceedings; Office on Women's Health; 2025 European Society of Endocrinology guideline.
Here's the part nobody explains clearly:
"Can she" and "will she" are two different questions. And the gap between them is where most women get stuck.
Why can a primary care doctor prescribe HRT without a menopause specialist license?
FDA-approved estrogen and progestogen products are prescription medications, but they are not federally controlled substances and are not reserved for gynecologists. Physicians can prescribe within their licenses; nurse practitioners and physician assistants can prescribe within the authority, collaboration, supervision, and formulary rules that apply in the state where the patient is located.
There is no federal menopause registry. There is no separate DEA category for estradiol or progesterone. There is no rule saying an OB-GYN must sign the prescription.
Family medicine and internal medicine already manage the things that shape a menopause decision: blood pressure, migraines, cardiovascular risk, medications, bleeding history, contraception, sleep, mood, thyroid disease, anemia, and cancer history. Academic and professional primary-care sources explicitly include menopause and hormone therapy within primary care and internal medicine practice. (Duke Health; American College of Physicians)
The state-law detail matters for NPs and PAs. Both groups prescribe across the country, but independence, physician agreements, and prescribing limits vary. That variation affects ordinary prescriptions as well as controlled substances; it is not only a testosterone issue. (AANP state practice map; AAPA state advocacy resources)
So the authority question is settled at the category level: primary care can do this. The appointment-level question is whether your clinician does.
What women are actually asking
These are real public-forum titles, not medical evidence:
- "Can my family doctor prescribe HRT?"
- "Do only OB/Gyns prescribe HRT? Or do others, like a General Practitioner, prescribe it?"
- "Who prescribes HRT? Regular doctor, functional doc, gyno etc?"
You are not the only person who did not know. That's the point.
Then why does it feel like you need a menopause specialist?
Because the training gap is real, even though the prescribing authority is not in question. A 2017 survey of residents in family medicine, internal medicine, and OB-GYN found that only 12 of 177 respondents felt adequately prepared to manage menopause, while 63 of 183 said they would not offer hormone therapy in a standard symptom scenario with no stated contraindication.
Let's sit with those numbers, because they change how you should read your own appointment.
The Kling survey was sent to 703 residents across 20 U.S. programs and had a 26% response rate. That means it is evidence of a serious education gap among the residents who answered; it is not a census of every current PCP or OB-GYN.
Four findings matter:
- 20.3% of respondents to that item reported receiving no menopause lectures during residency.
- 6.8% felt adequately prepared to manage menopause.
- 34.4% said they would not offer hormone therapy to a newly menopausal woman with symptoms and no stated contraindications in the survey scenario.
- 38.7% said they would prescribe hormone therapy through the average natural age of menopause for a woman with premature menopause.
That's not automatically a story about your doctor being dismissive. It is a story about a curriculum.
What one large health-system study found in actual visits
In October 2025, researchers presented an electronic-health-record study at The Menopause Society Annual Meeting involving nearly 5,500 women with an outpatient encounter carrying a menopause-related code.
Only 17.1% had a prescription treatment captured in the study data. Among those treated, 34% received systemic estrogen, 47% received vaginal estrogen, and 16% received an SSRI. Patients seen by OB-GYNs were most likely to receive systemic estrogen; internal medicine and family medicine visits were more likely to produce an SSRI. (The Menopause Society press release)
This was a conference poster based on one health system, not a peer-reviewed national estimate. “No prescription captured” does not prove the patient received no counseling, referral, or nonprescription plan.
But read the part the data does prove: more than eight in ten encounters did not end with a prescription treatment captured.
If that happened to you, it wasn't about you.
The result does not tell you to distrust primary care. It tells you to find out, early, whether this particular practice manages menopause.
It can still get better in one sentence
Ask this before the visit becomes a twenty-minute symptom history with nowhere to go:
“Do you evaluate and prescribe menopausal hormone therapy in this practice, or should I be seeing someone else?”
That question does not demand a prescription. It prevents a routing problem from pretending to be a medical decision.
Should you start with primary care or an OB-GYN for HRT?
Both can prescribe, so the real trade-off is access versus specialty pattern. In AMN Healthcare's 2025 survey of 1,391 offices across 15 major U.S. metro areas, the average new-patient wait was 23.5 days for family medicine and 42 days for OB-GYN. In a separate 2025 menopause-care study, OB-GYN encounters were more likely to produce systemic estrogen.
This is the trade-off nobody had put in one place. So we did.
The referral trade-off
| Decision fact | Family medicine | Internal medicine | OB-GYN |
|---|---|---|---|
| Average new-patient wait in 15 large metros, 2025 | 23.5 days | Not surveyed | 42 days |
| Change in average wait since 2022 | +14% | Not surveyed | +33% |
| Share of menopause-coded encounters in the 2025 health-system study | 12.4% | 17.6% | 64.4% |
| Prescribing pattern in that study | More likely than OB-GYN to prescribe an SSRI | More likely than OB-GYN to prescribe an SSRI | Most likely to prescribe systemic estrogen |
| Strongest practical advantage | Whole-person evaluation and usually faster access | Whole-person evaluation and medication review | Gynecologic examination, bleeding workup, and menopause-focused treatment experience |
Source: AMN Healthcare 2025 physician wait-time survey; The Menopause Society 2025 conference-poster summary. The table combines two different datasets as a routing lens; it does not prove that specialty alone causes either the wait or the prescription choice.
So here's the honest summary:
The faster door was the one less likely, in one recent health-system dataset, to hand you systemic estrogen. Which is exactly why you walk through it prepared.
That's the strategy. Not “skip your PCP.” Not “demand hormones.” Go to the appointment you can actually get, knowing what to ask and what the answer means.
When your regular doctor is the stronger first stop
Primary care has an advantage when the symptom could be hormonal or something else. Fatigue can sit beside anemia, thyroid disease, sleep apnea, depression, medication effects, or all five. Palpitations may belong in a menopause conversation, but they may also need a cardiac one. A PCP can keep the whole differential open instead of turning every symptom into an estrogen question.
Your own doctor also already has the chart. That can mean fewer records to reconstruct, a cleaner medication-interaction review, and easier coordination of blood pressure, preventive screening, and chronic conditions.
When an OB-GYN is genuinely the right first stop
Start with in-person gynecologic care when you have:
- Bleeding after menopause, or unexplained bleeding that has not been evaluated
- Pelvic pain, a vulvar or vaginal lesion, recurring urinary symptoms, or another problem that needs an examination
- A complicated gynecologic history, including prior endometrial disease
- Contraception needs that are difficult to separate from symptom treatment
- A surgical history you cannot reconstruct clearly
- A current gynecologic cancer concern or a history requiring coordinated specialist care
The version that often works best
It is not either/or. Many women keep primary care for medications, screenings, blood pressure, and the full picture, then add a menopause-focused clinician for the hormone decision.
If you use an online clinic, keep a local clinician for in-person examinations, imaging, urgent symptoms, and anything telehealth cannot physically assess.
Not sure which door is yours? The HRT Index's Find My HRT Path tool matches your situation to a starting route using your symptoms, age, uterus status, risk history, insurance, state, and preferred medication route. It also flags when online care is not the right starting point. The tool takes about 90 seconds, asks for no email, and stores nothing.
Where should you start based on your situation?
The right starting point depends less on the word “HRT” than on what is happening in your body and what must be ruled out first. The matrix below routes ten common situations to a reasonable first conversation; it does not diagnose menopause, determine candidacy, or replace a clinician's review of your history.
| Your situation | Start with | What primary care can do | When to escalate |
|---|---|---|---|
| 1. Hot flashes or night sweats at a usual menopause age, with no complex history | Your PCP | Review symptoms, timing, medicines, blood pressure, and FDA-approved hormonal and nonhormonal options | If the practice does not manage menopause or the symptom pattern is unclear |
| 2. Vaginal dryness, painful sex, or urinary symptoms only | PCP or OB-GYN | Evaluate for genitourinary syndrome of menopause and discuss low-dose local treatment | Pain, bleeding, a lesion, recurrent infection, or an uncertain diagnosis |
| 3. You still have periods and still need pregnancy prevention | PCP or OB-GYN who manages contraception | Treat symptoms while making a separate birth-control plan | Complex bleeding or limited contraceptive options |
| 4. You have a uterus and are considering systemic estrogen | Your PCP | Discuss endometrial protection with an appropriate progestogen or another approved strategy | Prior endometrial disease, unexplained bleeding, or treatment intolerance |
| 5. You have had a hysterectomy | Your PCP | Confirm what was removed and whether estrogen without a progestogen may fit | Unclear records, retained cervix or uterine tissue, endometriosis, or cancer history |
| 6. Bleeding after 12 months with no period, or unexplained vaginal bleeding | In-person evaluation first | Begin the workup and coordinate imaging, sampling, or gynecology | Do not route this through a self-serve hormone intake before the bleeding is assessed |
| 7. Personal history of breast, endometrial, or another hormone-sensitive cancer | Coordinated care with oncology and/or gynecology | Assemble records, medications, symptoms, and nonhormonal options | Treatment decisions are cancer-specific; reject anyone promising “always safe” or “never allowed” without your record |
| 8. Prior clot, stroke, heart attack, known thrombophilia, or active liver disease | An experienced in-person clinician | Compile the history, identify the exact contraindication or risk question, and discuss nonhormonal options | This needs individualized review, not a generic checkout flow |
| 9. Periods stopped before 45 — especially before 40 | PCP for evaluation; specialist input often helps | Evaluate for early menopause or primary ovarian insufficiency and address bone, cardiovascular, and fertility implications | Unclear diagnosis, fertility questions, induced menopause, or abnormal results |
| 10. Symptoms could also be thyroid, anemia, sleep, medication, or mood related | Your PCP — strongest advantage here | Keep more than one diagnosis open and order targeted testing | Severe, focal, progressive, or unexplained findings |
Editorial starting-point matrix based on current U.S. sources. Last verified August 26, 2026. Key sources: Office on Women's Health; ESE 2025 guideline; ACOG 2026 postmenopausal-bleeding update; current FDA-approved estradiol labeling example.
The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.
What kind of HRT can a primary care doctor prescribe?
A PCP can prescribe FDA-approved systemic estrogen, an appropriate progestogen when endometrial protection is needed, low-dose vaginal estrogen, vaginal prasterone, ospemifene, and prescription nonhormonal treatments when each is clinically appropriate. Compounded preparations and pellets belong to a separate regulatory category and should never be blurred with FDA-approved finished drugs.
Here's the map, organized around what is actually bothering you.
| What you are treating | FDA-approved options a PCP may prescribe | What changes the decision |
|---|---|---|
| Hot flashes and night sweats | Systemic estradiol by patch, gel, spray, or tablet; conjugated estrogens; combined estrogen-progestogen products; approved nonhormonal medicines | Age, time since menopause, uterus status, symptom burden, route preference, contraindications, interactions, and cardiovascular or clotting history |
| Endometrial protection when systemic estrogen is used | Micronized progesterone, another progestogen, or an FDA-approved combined product | Whether you have a uterus, bleeding history, dose, regimen, tolerance, and the exact estrogen product |
| Vaginal dryness, painful sex, or urinary symptoms | Low-dose vaginal estrogen by cream, insert/tablet, or ring; vaginal prasterone; ospemifene | Local therapy is a different dose and decision from systemic therapy; pain, bleeding, infection, or a lesion may require an examination first |
| Hot flashes when hormone therapy is not selected | FDA-approved nonhormonal treatments plus other evidence-based off-label options a clinician may discuss | Other medicines, liver or kidney function, blood pressure, sleep, mood, and side-effect profile |
| Low sexual desire | Diagnosis-specific treatment may include counseling, medication review, FDA-approved options for defined indications, or carefully selected off-label testosterone | Testosterone has no FDA-approved product specifically indicated for women in the U.S. and is a Schedule III controlled substance |
Source: FDA consumer overview of menopausal hormone therapies; exact product labeling through DailyMed.
Systemic means the medication is intended to circulate through the body and treat symptoms such as hot flashes. Local or vaginal therapy uses a lower dose intended mainly for vulvovaginal and urinary symptoms. They are not interchangeable.
Two prescriptions do not mean you are being “overmedicated.” A woman with a uterus may receive an estradiol patch plus a separate progesterone capsule because those are two jobs: symptom treatment and endometrial protection. The exact regimen is the clinician's decision, not a universal template.
What your PCP may decline to provide: pellets, custom-compounded creams, or “hormone optimization” packages built around broad proprietary testing. That is a difference in practice model, not proof that primary care is incapable of treating menopause.
Do you need blood tests before your doctor will prescribe HRT?
Usually not for the purpose of proving perimenopause or menopause when you are over 45 with a typical symptom and cycle pattern. Hormone levels fluctuate unpredictably during the transition, so a normal result does not rule it out. Testing matters when age, bleeding, pregnancy possibility, symptoms, or another suspected condition changes the question.
This one causes more unnecessary dead ends than almost anything else.
A woman goes in, gets a hormone panel, is told the number is “normal,” and is sent home. But a single draw is a snapshot of one morning during a transition defined by fluctuation. A normal FSH does not rule out perimenopause.
The Office on Women's Health says hormone blood tests are not usually recommended without a medical reason because levels rise and fall unpredictably. The 2025 European Society of Endocrinology guideline says biochemical testing is not necessary to diagnose or manage menopause in women over 45 with a typical presentation.
Testing is different when:
- You are under 40 with cycle disruption or estrogen-deficiency symptoms and primary ovarian insufficiency must be evaluated
- You are 40 to 45 and the diagnosis is unclear
- Pregnancy is possible
- The bleeding pattern needs evaluation
- A symptom points to thyroid disease, anemia, diabetes, a medication effect, or another condition
- A specific treatment requires baseline or follow-up monitoring
The tests that can change the plan
Not a universal “female hormone panel.” Targeted tests based on the history may include:
- Pregnancy testing when pregnancy is possible
- Thyroid testing when the symptoms or history point there
- A complete blood count and iron studies when bleeding or anemia is a concern
- Blood pressure and cardiovascular-risk assessment, with lipids or glucose/A1C when indicated
- Other testing driven by the symptom, treatment, or medical history
Vitamin D, iron, cortisol, testosterone, insulin, and broad panels are not automatic requirements for every woman asking about HRT. The test should answer a clinical question.
And a fair warning: be cautious with any program that sells a large hormone panel before it asks a real question. Testing should support the clinical picture, not replace it.
Did the FDA remove the boxed warnings from HRT?
Partly. On February 12, 2026, the FDA approved updated prescribing information for six menopausal hormone therapy products, removing boxed-warning statements about cardiovascular disease, breast cancer, and probable dementia from those labels. The FDA did not announce a blanket removal for every HRT product, and the endometrial-cancer warning remains for systemic estrogen-alone products.
This matters because it explains a specific kind of conversation.
Your doctor may be quoting a label. The question is which label.
What changed on February 12, 2026
The FDA approved revised prescribing information for:
- Prometrium — progestogen alone
- Divigel, Cenestin, and Enjuvia — systemic estrogen alone
- Estring — topical vaginal estrogen
- Bijuva — systemic estrogen plus progestogen
The agency said 29 companies had submitted proposed labeling changes. When The HRT Index rechecked the FDA's tracking page on August 26, 2026, it still listed those six products. (FDA announcement; FDA tracking page)
What did not change
- The FDA did not declare all menopausal hormone therapy risk-free.
- Other warnings and precautions remain in product labeling.
- The FDA did not seek removal of the boxed warning about endometrial cancer from systemic estrogen-alone products.
- A product not listed on the tracking page may still carry earlier boxed-warning language until its own label is changed.
So both of these are true:
- The FDA removed those three statements from the boxed warning on six products.
- “The FDA removed the boxed warning from HRT” is still an inaccurate blanket sentence.
How to check your own medication
Use DailyMed and search the exact product, strength, dosage form, and manufacturer on the package in your hand. Read the current boxed warning, contraindications, warnings, and label revision information for that product.
It takes a minute. It also stops a conversation about “HRT labels” from sliding past the label that actually governs your prescription.
What if your primary care doctor will not prescribe HRT?
A “no” can mean a clinical contraindication, a need for evaluation first, a practice policy, a training limit, or a factual assumption that can be checked. Those are not the same problem. Your next step is to identify which no you heard—not to argue until it becomes a yes.
We built this decoder because “my doctor said no” is not one problem. It is a group of different problems with different next moves.
| What you heard | What it may mean | What current evidence or labeling says | What to ask next | Different clinician? |
|---|---|---|---|---|
| “Your labs are normal, so this is not perimenopause.” | A single hormone result is being used as a gate | In women over 45 with a typical presentation, diagnosis is usually clinical; a normal FSH does not rule out perimenopause | “Can we evaluate this from my symptoms and cycle history instead of one hormone result?” | Not necessarily |
| “HRT causes breast cancer. It is in the black box.” | A broad claim may be standing in for a product-specific risk discussion | Six labels changed in February 2026; other labels may not have changed, and risks still require individualized discussion | “Which product label are we using, and what in my history changes the risk?” | Not necessarily |
| “You are too young because you still have periods.” | Perimenopause is being treated as a waiting room | Menopause symptoms can occur and be treated during perimenopause; pregnancy prevention is a separate decision | “What treatment options fit perimenopause while I still need contraception?” | Not necessarily |
| “It has been too long since your last period.” | Timing and baseline risk are driving caution | Age, time since menopause, symptoms, and health history change the benefit-risk discussion | “Can we walk through my timing and the options that remain?” | Sometimes |
| “Let's try an antidepressant first.” | A nonhormonal option is being favored | SSRIs/SNRIs can be legitimate options, but they are not the only option for every candidate | “Can we compare the hormonal and nonhormonal options side by side for my symptom?” | Not necessarily |
| “I do not prescribe menopause hormones.” | Practice scope or clinician comfort | The category is within primary care, but no individual clinician must offer every treatment | “Is there someone in this practice who does, or can you refer me?” | Usually, yes |
| “You need a gynecologist first.” | It may be a real examination need or a routing policy | Bleeding, pelvic findings, and complex gynecologic histories can justify that referral; otherwise ask what is driving it | “What specific finding makes gynecology necessary before we discuss treatment?” | Depends |
| “We only do pellets or custom bioidentical hormones here.” | The practice is built around compounded treatment | Compounded drugs are not FDA-approved; FDA does not verify their safety, effectiveness, or quality before marketing | “What FDA-approved finished-drug options treat this symptom?” | Possibly |
| “Insurance will not cover HRT.” | A formulary assumption may not have been tested | Coverage is product- and plan-specific; the visit and the prescription are separate claims | “Can we choose a covered product or have the pharmacy run the exact prescription?” | Usually no |
| “Let's wait and see.” | There may be no defined plan yet | Watchful waiting can be reasonable only when you know what is being watched, for how long, and what triggers action | “What are we waiting for, and when do we review this again?” | Not automatically |
Source: Office on Women's Health; ESE 2025 guideline; FDA 2026 labeling update; FDA compounding Q&A.
One rule before you use this: this is a decoder, not a script for overriding your doctor. Every row hands the decision back to a clinician. Your job is to make sure the conversation actually happened—not to win it.
Still not sure what kind of “no” you heard? Use Find My HRT Path to separate “needs in-person evaluation,” “practice does not manage this,” and “online menopause care may be a reasonable second route.” It does not diagnose you or promise a prescription.
When is “no” the right answer before starting HRT?
A clinician is right to pause when a symptom needs urgent care, bleeding needs evaluation, or the exact product's labeling lists a contraindication that applies. That is not dismissal. It is the point where the page must stop helping you push for a prescription and start helping you get the right evaluation.
We're going to be blunt here, because a page that only teaches women how to argue for hormones would be doing harm.
Get urgent help now for emergency symptoms
Chest pain, sudden shortness of breath, one-sided leg swelling, sudden weakness, facial droop, trouble speaking, or another possible clot, heart attack, or stroke symptom is not an HRT appointment. Call emergency services or go to urgent emergency care.
Get evaluated in person before routing this through online HRT care if you have
- Bleeding after menopause—meaning bleeding after 12 months without a period
- Unexplained vaginal bleeding that has not been assessed
- A new breast lump or nipple discharge
- Pelvic pain, a vulvar/vaginal lesion, or another symptom requiring examination
- A pregnancy possibility that has not been resolved
ACOG updated its postmenopausal-bleeding guidance in April 2026. Postmenopausal bleeding has many causes, and most are not cancer—but it is evaluated, not treated around. (ACOG)
Histories that can block a specific systemic product
Current systemic estrogen labeling commonly lists contraindications such as:
- Undiagnosed abnormal genital bleeding
- Breast cancer or another estrogen-dependent cancer, depending on the product
- Active or prior deep-vein thrombosis or pulmonary embolism
- Active or recent arterial thromboembolic disease such as stroke or myocardial infarction
- Liver dysfunction or disease
- A known thrombophilic disorder
- Pregnancy
Read the exact label, not a generic internet list. The wording and product category matter. (Current estradiol transdermal-system label example)
These are not debate prompts. If the exact product's labeling lists a condition as a contraindication, that product should not be prescribed. A different treatment—or, in selected cases, specialist-guided local therapy—may still be considered, but that is a new clinical decision.
“Not now” and “not ever” are different answers
Ask which one you received.
- Not now can mean the bleeding, blood pressure, diagnosis, records, or another condition must be addressed first.
- Not this product can mean another route or nonhormonal option deserves discussion.
- Not in this practice means a referral problem.
- Not ever should come with a clear medical reason tied to your history and the treatment being discussed.
A good clinician can tell you which answer she is giving.
How do you ask your primary care doctor for HRT?
Bring one page, describe one symptom pattern clearly, and name what you want evaluated. You are not asking the clinician to obey an internet protocol; you are asking whether menopausal hormone therapy is an option for you and whether this practice is willing and equipped to manage it. A defined follow-up plan turns a vague request into a clinical decision.
Open with these three sentences
- “I think I may be in perimenopause, and these symptoms are affecting my sleep, work, or daily life.”
- “I would like to discuss whether menopausal hormone therapy or another evidence-based treatment is an option for me.”
- “Do you manage menopause treatment in this practice, or should I see someone else?”
That third sentence is the most valuable one on this page. Ask it in the first two minutes. It can save an entire wasted appointment.
Bring the minimum history that changes the answer
| Bring this | Why it matters |
|---|---|
| Symptom list with start date, frequency, severity, and what the symptom is disrupting | Defines the problem being treated and makes follow-up measurable |
| Last menstrual period and recent bleeding pattern | Separates typical transition symptoms from bleeding that needs evaluation |
| Whether you still have a uterus, plus hysterectomy or ovary-removal details | Changes the endometrial-protection and early-menopause questions |
| Personal history of cancer, clots, stroke, heart attack, liver disease, migraine, and pregnancy possibility | Changes eligibility, product, route, and referral decisions |
| Current prescription medicines, over-the-counter products, and supplements | Identifies interactions and duplicate treatment |
| Whether you still need contraception | Menopausal hormone therapy is not birth control |
| Preferred pharmacy and insurance information | Lets the clinician choose an accessible product instead of an abstract one |
Ask five questions worth the appointment
- “Do you manage menopausal hormone therapy in this practice?”
- “What in my history changes the potential benefits, risks, or route for me?”
- “Are my symptoms systemic, local, or possibly caused by something else?”
- “Which FDA-approved options fit the symptom we are treating, and why that one?”
- “What is the follow-up plan, and what would make us adjust or stop it?”
What a good answer sounds like
She explains the treatment goal. She does not promise a result. She separates FDA-approved finished drugs from compounded products. She asks whether you have a uterus before prescribing systemic estrogen. She tells you what is unknown. She gives you a review date and a way to report a problem.
A good answer can still be no.
What makes it good is that the no belongs to your history, the product, or a defined practice limit—not a vague sentence about women your age.
Meredith Burris, an Atlanta attorney interviewed by Fortune, described raising insomnia, hair loss, back pain, weight gain, and what she called rage symptoms at 46, only to be told it was “just a part of life.” She ultimately reached a clinician listed by The Menopause Society after two years and three doctors. That is one reported access experience, not a typical result or evidence that a treatment will work for someone else. (Fortune)
What not to do
Do not lead with a protocol from a supplement seller. Do not present a mail-order hormone panel as a diagnosis. Do not insist on a compounded formula or pellet because a creator called it “bioidentical.” Those moves force the appointment into a fight over somebody else's product before your clinician has even evaluated your symptom.
Copy this into your phone before the visit
My main symptom:
When it started:
How often it happens:
What it is disrupting:
My last period / current bleeding pattern:
Uterus present? Surgeries?
Cancer, clot, stroke, heart, liver, migraine, or pregnancy history:
Do I still need contraception?
My request: “Please evaluate whether menopausal hormone therapy or another evidence-based treatment fits my situation.”
My routing question: “Do you manage this here?”
My follow-up question: “When do we review whether the plan is working?”
That is the appointment card. No account. No download gate. No email capture. Just use it.
Does insurance cover HRT from a primary care doctor?
Often, but there are two separate coverage decisions: the visit and the prescription. A PCP visit is processed under the practice and your medical benefit; the medication is processed by the pharmacy under your drug benefit. The exact copay, deductible, formulary tier, prior authorization, and covered product depend on your plan.
Two bills. Two systems. People conflate them constantly.
The visit is billed as a primary-care or specialist office visit, depending on the clinician and plan.
The medication runs through the pharmacy benefit, unless you choose a cash price instead.
Here is the sentence that reframes the category:
The prescription is often the cheap part. The appointment is the care you are actually buying.
What each route really charges for
| Route | What the care charge buys | How the medication is paid | What can recur |
|---|---|---|---|
| Your own PCP + your pharmacy | Office evaluation, prescribing, and follow-up | Insurance pharmacy benefit or cash price at your chosen pharmacy | Copays, deductible, follow-up visits, and medication refills |
| Insurance-billing menopause telehealth | A menopause-focused visit, care plan, and follow-up | Usually your own pharmacy benefit when the prescription is sent out | Visit cost; no membership at the providers compared below |
| Medication-bundled subscription | Access plus medication and sometimes messaging | Included in a recurring program charge | Subscription charges until cancellation under the program's terms |
A coupon-site medication price can change by location, pharmacy, quantity, manufacturer, and day. We removed volatile coupon figures from this page rather than pretending a one-day screenshot is a durable price. Use your plan or pharmacy's live quote for the exact product, strength, quantity, and location.
Before you leave the appointment
- Ask the clinician to prescribe the covered product, not only a brand name you saw online.
- Ask the pharmacy to process the exact prescription before you assume it is excluded.
- Ask whether a prior authorization or step requirement applies.
- If the brand is medically necessary, ask the office what documentation the plan requires.
- HSA/FSA eligibility depends on the expense and your plan; keep the receipt and check your administrator's rules.
How long the route can take
If you already have a PCP and can get an appointment, the path may be one visit, a prescription to your pharmacy, and a follow-up after the clinician's chosen interval. What adds time is the appointment wait, bleeding evaluation, a targeted lab, prior authorization, records retrieval, or a pharmacy supply problem.
The AMN survey's 23.5-day family-medicine average applies to new patients in 15 major metro areas, not to every established patient or every U.S. town. Use it as a pressure gauge, not a promise.
Can a primary care doctor prescribe testosterone for women?
A PCP may prescribe testosterone when state law, the clinician's license, DEA registration, clinical judgment, and practice policy allow it. FDA states that approved testosterone products are approved only for men with low testosterone tied to an associated medical condition; no product is FDA-approved specifically for women in the United States, so use in women is off-label. Testosterone is also a Schedule III controlled substance with federal prescription, refill, and telemedicine rules. (FDA testosterone information)
Three constraints stack up here.
1. There is no female-labeled FDA-approved testosterone product in the U.S.
Off-label prescribing can be lawful and appropriate, but it means the clinician is using an approved drug outside its approved population, indication, dose, or dosage form. The decision rests on evidence, clinical judgment, informed consent, product selection, dosing, and monitoring—not on a product label written for women.
2. Testosterone is Schedule III
The DEA lists testosterone as an anabolic steroid in Schedule III. Federal rules limit a Schedule III prescription to no more than five refills within six months after the prescription date; state law can be stricter. (DEA drug scheduling; 21 C.F.R. §1306.22)
That means a legitimate service must treat it as a controlled prescription. A questionnaire alone is not the prescription. A clinician must evaluate you, hold the required authority, and comply with federal and state rules.
3. Telemedicine rules remain time-sensitive
The DEA and HHS extended the temporary federal telemedicine flexibilities that can allow prescribing of controlled medication without a prior in-person medical evaluation through December 31, 2026, subject to the rest of federal and state law. (DEA extension)
Do not build a long-term testosterone plan around the assumption that today's no-prior-exam pathway will remain unchanged. The durable route is a clinician who can continue caring for you under whatever rules apply next—often an established local prescriber or a telehealth practice with a clear in-person contingency.
If testosterone is part of what you want, ask before paying:
- Does this clinician prescribe testosterone for women in my state?
- Is an in-person examination required now or if federal rules change?
- Which product is used, and is it being prescribed off-label?
- What monitoring and follow-up are required?
- What happens if the clinician decides it is not appropriate?
This is the hormone on the page where “can prescribe” most clearly does not mean “will prescribe.”
Can a primary care doctor prescribe compounded hormones or pellets?
Some can, but compounded drugs are not FDA-approved finished products and the FDA does not verify their safety, effectiveness, or quality before they are marketed. ACOG says compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations exist. Pellets add a procedure and cannot be adjusted as easily as a daily patch, pill, gel, or cream.
The words in this category are deliberately slippery. Here is the clean ladder.
| Term | What it actually tells you |
|---|---|
| FDA-approved finished drug | The FDA reviewed that specific finished product for its approved use, labeling, manufacturing, quality, safety, and effectiveness before marketing |
| 503A patient-specific compounded drug | A pharmacy compounds for an identified patient under applicable federal and state rules; the finished drug is not FDA-approved |
| 503B outsourcing-facility compounded drug | The facility registers with the FDA and follows additional federal requirements; registration does not turn each compounded drug into an FDA-approved product |
| “FDA-registered,” “FDA-regulated,” or made with an approved ingredient | A statement about a facility, ingredient, or regulatory relationship—not FDA approval of the finished compounded medication |
Source: FDA compounding Q&A; ACOG Clinical Consensus on compounded bioidentical menopausal hormone therapy.
Note what the bottom three rows do not say: approved finished drug.
When compounding can be a legitimate answer
The FDA describes compounding as an option when an approved drug cannot meet a patient's medical need—for example, a required dosage form or an excipient problem that available approved products cannot solve. That is different from choosing compounding because a marketing page calls it personalized, natural, or more precise.
Ask the prescribing clinician:
- What medical need cannot be met by an FDA-approved finished product?
- What is the exact ingredient, concentration, dosage form, and pharmacy?
- Is the final medication FDA-approved? The answer for a compounded drug is no.
- How will dose consistency, adverse effects, and follow-up be handled?
- What is the total recurring cost?
Before anyone implants a pellet
Ask what is in it, the dose, whether the finished product is FDA-approved, how adverse effects will be handled after implantation, how long the implant is expected to release medication, and what the next procedure costs.
The practical difference is not philosophical. A patch can be removed. A tablet can be stopped. A pellet has already been implanted.
What are your options if your own doctor is not one of them?
If your PCP does not manage menopause, has declined without a clinical reason, or is not available soon enough, you still have three useful routes: an insurance-billing menopause clinic, telehealth primary care, or a local menopause-trained clinician. The right route depends on plan coverage, state availability, medication category, and whether you need an examination first.
Before the table, our money:
Midi is an active affiliate and may pay The HRT Index if you use our sponsored link. MyMenopauseRx, Elektra Health, Circle Medical, and Gennev do not pay us for placement on this page. Winona and Inner Balance are also active affiliates, but we are not routing them as the primary answers here: Winona states that it offers both FDA-approved products and compounded creams, while Inner Balance states that Oestra is compounded, so Oestra is not an FDA-approved finished drug. This table is deliberately focused on visit-based routes that publicly document pharmacy-dispensed or FDA-approved prescribing.
That is the damaging admission. We could route every reader to the highest-paying offer. We are not doing that.
Provider-stated versus verified route comparison
| Provider | Care model | Insurance and government-plan position | Published self-pay visit price | Medication/formulary statement | Membership fee | Sends prescriptions to your pharmacy | Pays us? |
|---|---|---|---|---|---|---|---|
| Midi Health | Menopause-focused telehealth | In-network with most PPO plans; Medicare is out of network but beneficiaries may self-pay; Medicaid and Medi-Cal patients cannot be treated, even as self-pay | $250 first / $150 return | Evaluates and prescribes when clinically appropriate; medication and labs are separate costs | None | Yes | Yes |
| MyMenopauseRx | Menopause-focused telehealth | Publishes in-network commercial PPO plans; does not accept Medicare, Medicaid, or HMO plans | $150 per video visit | Publishes FDA-approved estradiol and progesterone prescribing; sends prescriptions to the patient's pharmacy | None | Yes | No |
| Elektra Health | Menopause-focused telehealth | Select commercial, Medicare, and Medicaid plans in listed states; coverage is plan- and state-specific | $249 first / $149 follow-up | Publishes an FDA-approved-only prescribing policy for hormonal and nonhormonal medication | None | Yes | No |
| Circle Medical | Telehealth primary care | Accepts many insurance plans; cannot accept Medicaid or Medi-Cal patients even as self-pay | $120 per appointment | Primary-care evaluation with medication support when clinically appropriate | None | Yes | No |
| Gennev | Menopause-focused telehealth | Accepts insurance plans listed by market; confirm the exact plan before booking | $250 first / $199 follow-up | Publishes FDA-approved hormonal and nonhormonal medication pathways | None | Yes | No |
Provider-stated facts verified August 26, 2026 from Midi, MyMenopauseRx and its FAQ, Elektra Health, Circle Medical, and Gennev. Insurance networks and state availability can change; confirm through the provider's eligibility flow and your plan before booking.
None of the cash visit prices above is a medication bundle. Prescriptions go through a pharmacy, and lab work—when ordered—can create a separate charge under insurance or cash-pay terms. Confirm the lab network, estimated patient responsibility, and medication coverage before the clinician submits an order.
Appointment cancellation terms can still cost you
| Provider | Publicly stated appointment term checked August 26, 2026 |
|---|---|
| Midi | Rebook or cancel at least 24 hours ahead to avoid a cancellation fee; the public page we found does not state the amount. (Midi) |
| MyMenopauseRx | Cancel at least 24 hours ahead; a cancellation within 24 hours carries a nonrefundable $99 fee. (MyMenopauseRx) |
| Elektra | Cancel or reschedule at least 24 hours ahead to avoid a $50 charge. (Elektra) |
| Circle Medical | The linked menopause page publishes no membership fee and charges after a completed appointment, but it does not state a late-cancel or no-show fee. Confirm the live booking terms. (Circle Medical) |
| Gennev | Two current help pages describe different events: $100 for cancellation or rescheduling within 24 hours, and $50 for a no-show without cancellation. Confirm which rule applies before booking. (late cancellation; no-show fee) |
This is why “no membership” does not mean “no policy risk.” Save the confirmation email and cancel inside the stated window.
The honest limitation on our own recommendation
Midi cannot treat Medicaid or Medi-Cal patients, even if they want to self-pay. Midi also does not bill Medicare—but its current pricing page says Medicare beneficiaries may book as self-pay patients and may not submit Midi-related claims.
That means the fork is not “Medicare patients cannot use Midi.” The accurate fork is:
- Medicaid or Medi-Cal: Midi is not available.
- Medicare: Midi is a cash-pay option, not a Medicare-covered visit.
- Commercial insurance: coverage depends on the exact plan and network.
- Self-pay: $250 for the first visit and $150 for a return visit, with medication and labs separate.
If Medicare or Medicaid coverage is the deciding factor, Elektra publishes participating government plans in selected states. Check the exact state and plan; do not treat “accepts Medicare/Medicaid” as a nationwide blanket.
If you have commercial insurance and your PCP has declined because the practice does not manage menopause, Midi is the cleanest sponsored second route on this page: no mandatory subscription, prescriptions sent to your pharmacy, and a plan-coverage check before booking.
Commercial insurance or Medicare self-pay: Check Midi's current coverage and visit pricing → (sponsored link; Midi may pay The HRT Index)
Commercial insurance with a $150 cash fallback: Check MyMenopauseRx coverage and current visit terms → (editorial link; no commission)
Selected Medicare or Medicaid plans: Check Elektra's live state-and-plan list → (editorial link; no commission)
The option almost nobody mentions
Circle Medical is primary care by video. If your problem is “I do not have a PCP” rather than “my PCP refused HRT,” establishing telehealth primary care can be cleaner than joining a medication-bundled menopause subscription. Circle publishes $120 self-pay visits, no membership fee, and an average insurance out-of-pocket figure of $35 that it labels as an estimate—not a guaranteed price.
Gennev's clean use case
Gennev publishes 30-minute physician visits at $250 initially and $199 for follow-up, plus insurance participation by plan. It is a strong fit when you want menopause-focused physician care and can verify network coverage or accept the cash price.
One thing to ask any service before you pay
A visit buys an evaluation, not a prescription. Ask when the card is charged, what the cancellation deadline is, whether the fee is refundable, whether medication and labs are separate, and what happens if the clinician decides you are not a candidate.
MyMenopauseRx, for example, publishes a $99 late-cancellation/no-show fee. Do not confuse that fee with the visit price: its current self-pay video visit is $150.
Can your PCP take over an HRT prescription you received online?
Often, but never automatically. A PCP must independently review the medication, diagnosis, dose, monitoring, contraindications, and follow-up before agreeing to continue it. She can accept the regimen, change it, move you to an FDA-approved alternative, or decline to take responsibility for it.
This is the move that solves a problem many women do not see coming: online care is the fast start, then insurance, continuity, or one-chart care becomes more valuable than speed.
Make the handoff easy:
- Request your records before canceling the online service.
- Bring the exact product, strength, dosage form, schedule, and dispensing pharmacy.
- Bring the date you started, symptom response, side effects, and every dose change.
- Bring any labs, blood-pressure readings, imaging, or visit notes the online practice used.
- If you have a uterus and use systemic estrogen, identify the exact endometrial-protection plan.
- Ask when the PCP would want the next follow-up and who handles refills during the transition.
- Do not cancel first and solve continuity later. Leave enough time for records, an appointment, and a legitimate prescribing decision.
If the online prescription is compounded, your PCP may recommend switching to an FDA-approved finished product that meets the same clinical need. Do not call that product an “equivalent” unless the clinician or FDA-recognized labeling actually supports equivalence.
Your PCP is not being difficult by re-evaluating a prescription started elsewhere. Taking over the refill means taking over the medical responsibility.
How do you find a doctor who actually knows menopause?
The clearest searchable credential is MSCP—The Menopause Society Certified Practitioner—but it is a competency credential, not a medical license or a guarantee that the clinician is the right fit. The public directory is useful and incomplete: inclusion is voluntary, clinicians not accepting new patients may be excluded, and The Menopause Society does not endorse individual listings.
A licensed healthcare professional can sit for the competency examination if eligible under The Menopause Society's rules, and the credential is valid for three years. Always check the person's underlying license and whether that license allows prescribing in your state. (The Menopause Society: Choosing a Healthcare Practitioner)
Three limits of the directory
- It is opt-in. A qualified or certified clinician may not appear.
- It reflects availability filters. An empty local result does not prove no trained clinician exists nearby.
- It is not an endorsement. You still need to evaluate licensure, scope, medication model, costs, and fit.
And plenty of excellent clinicians do not hold MSCP. Do not treat its absence as automatic disqualification. Ask what menopause education they have, how often they manage menopausal hormone therapy, which FDA-approved formulations they prescribe, how they handle abnormal bleeding, and whether they coordinate with primary care.
Also ask your own doctor. She may hold the credential, know who in the practice does, or know the local referral that never appears in a search result.
Search The Menopause Society practitioner directory → (free directory; no commission)
What did The HRT Index actually verify for this page?
The HRT Index editorial team checked the central medical, regulatory, wait-time, and commercial claims against current primary or first-party sources on August 26, 2026. This is editorial research, not medical advice, and the page has not been medically reviewed by a clinician. Commercial details are separated from medical claims and dated because they can change without notice.
We applied The HRT Index Verification Standard across five pillars in this order: clinical legitimacy, care quality, medication fit, price transparency, access.
Medical and regulatory checks
- Prescribing route: academic primary-care and internal-medicine sources confirming that PCPs manage menopause and can prescribe hormone therapy.
- Training data: Kling et al., Mayo Clinic Proceedings, including the sample, response rate, and item-specific denominators.
- Treatment-pattern data: The Menopause Society's October 2025 press release for a conference poster; labeled as one health-system study and not peer-reviewed.
- Wait times: AMN Healthcare's 2025 survey of 1,391 offices in 15 large metros.
- Hormone testing: the federal Office on Women's Health and the 2025 European Society of Endocrinology guideline.
- Postmenopausal bleeding: ACOG's April 2026 update.
- FDA labeling: the February 12, 2026 FDA announcement and the live FDA product-tracking page, rechecked August 26, 2026.
- Contraindications: current FDA-approved product labeling through DailyMed.
- Compounding: FDA compounding guidance and ACOG's 2023 Clinical Consensus.
- Testosterone: DEA scheduling, federal refill rules, and the temporary telemedicine extension through December 31, 2026.
Commercial checks
We read each provider's own pricing, insurance, formulary, lab, state-availability, and appointment-policy pages on August 26, 2026. Five live details materially change the routing:
- Midi's Medicare rule is self-pay permitted, no Medicare claims—not a total Medicare ban.
- MyMenopauseRx is $150 per self-pay video visit; $99 is its published late-cancellation fee inside 24 hours.
- Gennev is $250 for a first physician visit and $199 for follow-up, not $199 initially; its help pages separately publish a $100 late-cancel/reschedule charge and a $50 no-show fee.
- Circle Medical publishes $120 self-pay per appointment and labels $35 as an average insurance out-of-pocket estimate.
- The listed visit prices are not medication bundles, and labs ordered during care can create a separate insurance or cash charge.
What this page deliberately does not claim
- No provider is called available in all states unless its live page says so.
- No insurance logo is treated as proof that your plan is in network.
- No coupon price is presented as a durable medication cost.
- No visit is presented as a guaranteed prescription.
- No compounded medication is described as FDA-approved or equivalent to an approved finished drug.
- No numeric provider score, fake review, or fabricated medical reviewer appears here.
Affiliate relationships are disclosed on the page and in the site's affiliate disclosure. A commercial relationship does not change the factual standard or the reader's need to verify plan coverage before booking.
Frequently asked questions
Can a primary care doctor prescribe HRT?
Yes. A family medicine or internal medicine clinician can evaluate menopause symptoms and prescribe FDA-approved menopausal hormone therapy when it is clinically appropriate and within that clinician's state scope. You do not automatically need an OB-GYN.
Can my GP prescribe HRT?
Yes. “GP,” family doctor, and primary care doctor describe the same basic route for this U.S.-focused question. The variable is not a special menopause license; it is the clinician's state authority, experience, and practice policy.
Do I need a referral to get HRT?
There is no universal rule requiring an OB-GYN referral before menopausal hormone therapy. Your insurance plan may require a referral for a specialist or telehealth clinic, and a PCP may refer when your history or symptoms need specialist input.
Is a gynecologist better than a primary care doctor for menopause?
Not automatically. Primary care can be faster and better at evaluating overlapping causes; gynecology is stronger when you need a pelvic examination, bleeding workup, complex gynecologic review, or a clinician who manages menopause more often. Many women use both.
Can a nurse practitioner prescribe HRT?
Yes, when the NP's state scope, license, and practice arrangement permit it. The level of independent practice and required physician involvement varies by state.
Can a physician assistant prescribe HRT?
Yes, within the PA's state authority and practice arrangement. State law and the supervising or collaborating structure can affect how the prescription is issued.
What blood tests do I need before starting HRT?
There is no universal hormone panel required for women over 45 with a typical menopause-transition presentation. Testing should answer a specific question, such as pregnancy, thyroid disease, anemia, diabetes risk, early menopause, unusual bleeding, or monitoring for a selected treatment.
Why will my doctor not prescribe HRT?
The reason usually falls into one of five groups: a product contraindication, a symptom needing evaluation first, a practice policy, limited menopause training, or a different treatment recommendation. Ask which one applies and what evidence or finding drives it.
Can my doctor prescribe HRT if I am still having periods?
Yes. Perimenopause symptoms can be treated before the final menstrual period. Menopausal hormone therapy is not contraception, so pregnancy prevention must be handled separately while pregnancy remains possible.
Can a primary care doctor prescribe vaginal estrogen?
Yes. PCPs can prescribe FDA-approved low-dose vaginal estrogen when appropriate. Vaginal bleeding, pain, a lesion, recurrent infection, or an uncertain diagnosis may require an examination first.
Do I need a pelvic exam before starting HRT?
Not every woman needs a new pelvic exam solely because she asked about systemic hormone therapy. An examination becomes relevant when symptoms, bleeding, screening status, or history point to something that must be assessed physically. Ask whether the exam is required for a specific reason or simply recommended as routine care.
Do I need a mammogram before starting HRT?
Breast screening should follow the schedule appropriate to your age and risk, and a clinician may need to evaluate a breast symptom before treatment. There is not one universal internet rule that every woman must complete a new mammogram immediately before any HRT prescription.
Can a primary care doctor prescribe testosterone for women?
Potentially, but the constraints are greater. FDA states that approved testosterone products are approved only for men with low testosterone tied to an associated medical condition; no product is FDA-approved specifically for women in the U.S. Use in women is off-label, testosterone is Schedule III, the clinician needs appropriate DEA and state authority, and follow-up and refill rules apply.
Does insurance cover HRT prescribed by a PCP?
Often, but the visit and medication are separate benefits. Check whether the clinician is in network, whether the exact medication is on the formulary, and whether prior authorization or a deductible applies.
Can my PCP continue an HRT prescription from an online clinic?
Often, but the PCP must independently agree to take it over. Bring records, the exact product and dose, response and side effects, lab or blood-pressure data, and the endometrial-protection plan if you have a uterus.
What if I do not have a primary care doctor?
You can establish local primary care, use telehealth primary care such as Circle Medical where available, book a menopause-focused insurance clinic, or search The Menopause Society directory. Bleeding, urgent symptoms, or an examination need should route you to in-person care first.
Did the FDA remove the warnings on HRT?
The FDA approved removal of three boxed-warning statements from six product labels on February 12, 2026. It did not remove every warning from every HRT product, and the endometrial-cancer boxed warning remains for systemic estrogen-alone products.
The bottom line
Yes—a primary care doctor can prescribe HRT. For many women, the doctor who already knows their history, accepts their insurance, and can send an FDA-approved prescription to their chosen pharmacy is the cleanest place to start. The question is not whether primary care is allowed to do it. The question is whether this practice does it well.
Take three things with you:
- The authority usually is not the wall. Training, practice scope, and the need for evaluation are.
- Ask whether the practice manages menopause in the first two minutes. That question can save a wasted visit.
- A no has a meaning. Decode it before accepting it—and when it is about bleeding, an emergency symptom, or an exact contraindication, take it seriously.
If the answer is “not in this practice,” that is not the end of the road. It is a routing decision.
Still not sure which HRT program is right for you? Use Find My HRT Path. It takes about 90 seconds, requires no account or email, stores nothing, and tells you when online care is not the right starting point.
The HRT Index publishes independent editorial research for women comparing menopause and HRT care. This page is educational, is not medical advice, and has not been medically reviewed by a clinician. Talk with a qualified clinician about your own symptoms, history, and treatment options.